# Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

Study · id `cardio:ct-nct07830719` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07830719](<https://clinicaltrials.gov/study/NCT07830719>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07830719

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07830719. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-18 (actual); primary completion 2027-08-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07830719, source copy `cardio:ctgov-nct07830719-2026-10-15`, retrieved 2026-10-26)
- Started: 2026-09-18 (actual) (ClinicalTrials.gov record NCT07830719, source copy `cardio:ctgov-nct07830719-2026-10-15`, retrieved 2026-10-26)
- Primary completion: 2027-08-15 (anticipated) (ClinicalTrials.gov record NCT07830719, source copy `cardio:ctgov-nct07830719-2026-10-15`, retrieved 2026-10-26)
- Completion: 2027-08-15 (anticipated) (ClinicalTrials.gov record NCT07830719, source copy `cardio:ctgov-nct07830719-2026-10-15`, retrieved 2026-10-26)
- Countries: United States; Australia; Germany; Japan; United Kingdom (ClinicalTrials.gov record NCT07830719, source copy `cardio:ctgov-nct07830719-2026-10-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07830719-2026-10-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
- Condition: Coronary Artery Disease
- Intervention (Drug): YMI024
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 280678c82037bad070dc60215b05c6088cd358774637c93803454fbe00c7b727
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
